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Abstract
Background: Community-dwelling persons with dementia commonly use dietary supplements (DS), often without
receiving help with the administration. Patient safety is a concern, as DS-drug interactions and adverse events are
potential complications. Since many persons with dementia buy their DS in pharmacies, we investigated Norwegian
pharmacy employees’ attitudes and professional practice behaviors related to DS.
Methods: We conducted a survey in eight Norwegian municipalities of pharmacy employees involved in the sale
of DS. The questionnaire covered demographics and investigated attitudes toward DS, professional practice
behaviors related to the sale of DS, experiences with customers with dementia, and perceived and attributed
responsibilities with regard to patient safety.
Results: One hundred and five employees responded (response rate: 52%). Most employees regarded general
practitioners (GPs) as primarily responsible for safeguarding the use of DS by persons with dementia and rated
themselves less responsible. Thirty-seven percent of the employees reported personal use of DS (past or current
use). Nine percent considered some of the DS to have symptomatic or prophylactic effects against dementia. Forty-
eight percent confirmed that they informed customers about potential adverse events; 42% indicated that they did
this sometimes. Sixteen percent checked regularly for DS-drug interactions, and two-thirds checked depending on
the customers’ health, the type of drug or the type of DS. One-quarter regularly asked about the co-use of
prescription drugs (PD) when selling DS, while only 2% asked about the co-use of DS when dispensing PD. Only
25% reported access to independent scientific information on all or most DS sold in their pharmacy. Eight percent
had experienced unsafe use of DS by persons with dementia. Six percent had been taught about counselling
persons with dementia. Education level influenced professional practice behavior to some extent.
Conclusion: Pharmacy employees do not see themselves as primarily responsible for the safe use of DS by persons
with dementia. Moreover, they have limited experience with the unsafe use of DS by these persons. There is
potential for improvement regarding tools and educational interventions for pharmacy employees to provide
sufficient help to persons with dementia who use DS.
Keywords: Pharmacy, Dietary supplements, Dementia, Patient safety, Risk management, Professional practice
behavior, Attitude, Attributed responsibility, Cross-sectional survey
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Background
Dietary supplements (DS) include vitamins, minerals,
herbs, amino acids and dietary substances [1]. DS are
widely used in the general population [2, 3], often for
maintaining or improving health [4]. Considered natural
and safe by many, DS can nevertheless compromise
patient safety through interactions with prescription
drugs (PD) and by causing direct adverse events [5, 6].
Fatal events have been reported [7].
Dementia is a general term for progressive diseases
that affect mental abilities and cause problems in
activities of daily living (ADL). The majority of persons
with dementia have Alzheimer’s disease, with memory
problems as the most common symptom [8]. Several DS
claim to protect against cognitive decline and dementia,
such as omega-3 fatty acids and antioxidants like
Vitamin E and Vitamin C, but the scientific evidence is
sparse [9, 10]. DS is commonly used by community-
dwelling persons with dementia, and studies report a
prevalence of 50% [11, 12]. Potentially clinically relevant
interactions between DS and PD have been reported in
11–33% of persons with dementia who use DS [6, 12].
Due to reduced cognitive function, persons with demen-
tia are at risk of misdosing or confusing DS with PD or
vice versa, imposing additional risks on this particular
patient group. Another concern is that two-thirds of per-
sons with dementia using DS receive no help with their
DS, even though most of them receive help with admin-
istering their PD [12].
General practitioners (GPs) have the responsibility for
patients’ health and safety, including their PD [13]. Their
responsibility regarding DS is less clear [4]. Patient
autonomy is a very strong principle within medical
ethics [14], thus patients may freely choose to use DS.
However, persons with dementia are often incapable of
safeguarding their own use of DS [12]. They may have
difficulties in making an informed choice about the use
and administration of DS. When patients are not able to
take responsibility, who should then be responsible?
Should the responsibility rest with the DS retailers who
are not a part of the traditional health-care system
(hereafter denoted DS retailers), patients’ caregivers, or
health-care personnel (e.g., GPs, the home care service
or pharmacy employees)? If no one accepts this respon-
sibility, the patient him- or herself will be left respon-
sible. The caregiver might take the initiative for the DS
use [12], and can additionally help the patient administer
the DS and communicate with the health-care system.
Caregivers are an important unpaid care resource [15]
but are not expected to have knowledge regarding PD or
DS. Furthermore, the DS-retailers should be responsible
for giving correct information about the DS content
[16], but are not expected to possess knowledge on
dementia. We identified GPs, pharmacy employees and
the home care service (nurses and nurse assistants) as
relevant to this responsibility. These health-care profes-
sionals are authorized to work with PD, and the safety of
DS use is closely connected to the PD used. We have
restricted our research interest to primary health care
because it is the backbone of the Norwegian health care
system. Furthermore, several patients with late-onset
dementia, are diagnosed at the primary health care level
and might not have any contact with the specialist
health care system.
In Norway, as in several other Western countries,
caring for older adults is now in many cases maintained
by professional health-care workers, i.e., the home care
service, and not by relatives or next of kin. According to
Statistics Norway, more than 73% of Norwegian women
aged 80 years and older live alone, while 31% of Norwe-
gians (men and women) between 67 and 79 years old live
alone [17]. At present, health-care personnel are seldom
aware of, or involved in, patients’ DS use [2, 5, 11].
Health-care personnel are obliged to ensure that their
patients with cognitive impairments avoid harmful use
of PD, but whether health care personnel should also be
obliged to take responsibility for the safe use of DS has
not, to our knowledge, been addressed previously.
As most pharmacies trade a variety of DS, pharmacy
employees are often involved in the sale of DS, [18, 19].
Pharmacists often receive questions about DS from cus-
tomers, but they neither routinely inquire about DS use,
nor monitor or document DS use [20]. Previous publica-
tions have revealed room for improvement regarding
pharmacists’ knowledge of DS [20, 21]. Most studies
regarding pharmacy employees’ experiences with sale/
counselling of DS have included only pharmacists as
informants. However, employees with other types of
educational backgrounds commonly sell DS. We identi-
fied only one study in the English language that included
pharmacy technicians [22]. Employees with other educa-
tional backgrounds than pharmacists account for half of
the employees in Norwegian pharmacies [23].
We have previously documented that one-third of
persons with dementia recruited from a Norwegian out-
patient memory clinic bought their DS in pharmacies
[12]. There is a paucity of information about pharmacy
employees’ experiences in counselling persons with
dementia as part of their daily routine [24]. Even less is
known about their experiences counselling persons with
dementia or their caregivers about DS. Thus, it is im-
portant to explore how pharmacy employees could assist
in risk management of DS use in older adults, either by
direct counselling or in collaboration with GPs and
home care services.
The aim of this study was to describe Norwegian phar-
macy employees’ attitudes and professional practice be-
haviors related to the counselling and sale of DS in
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general and, more specifically, to persons with dementia.
We also investigated to which degree pharmacy em-
ployees felt responsible for the safety of customers with
dementia buying DS.
Methods
Study population and recruitment
We conducted a cross-sectional survey from December
2014 to March 2015. All pharmacy employees in eight
municipalities in Northern Norway were invited to par-
ticipate. There were 23 pharmacies in this geographical
area (one hospital pharmacy and 22 community pharma-
cies). All but one pharmacy agreed to participate; see
Fig. 1 in Result section. The eight municipalities were
chosen because they provide the source population for
the memory clinic where our research group recently
conducted a study of the use of DS by persons with
dementia [12]. The present study and further studies
among other health-care personnel (GPs and home care
service employees) were therefore conducted in the
same geographical area.
Employees holding a bachelor’s (three years) or
master’s (five years) degree in pharmacy were classified
as pharmacists, while employees with other educational
backgrounds (e.g., upper secondary school) were classi-
fied as pharmacy technicians. We excluded employees
without customer contact as part of their daily work.
The master’s degree is equivalent to the pharmacist
degree across Europe, while the pharmacy bachelor
normally qualifies for work as a dispensing pharmacist
in community pharmacies. Two of the respondents
stated in the open-ended question that they were nurses.
Nurses have valuable knowledge that can be used as a
resource in pharmacies. In this study, we wanted to
Fig. 1 Flowchart of study population and recruitment process
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ascertain whether there were differences between phar-
macists and other employees because we anticipated
pharmacists to possess a greater knowledge level regard-
ing adverse events from PD and DS, as well as interac-
tions. Because nurses are not expected to possess the
same level of knowledge as pharmacists about these
topics, we chose to classify them as pharmacy techni-
cians. In Norway, all health-care personnel are profes-
sionals, as they need to apply and receive accreditation
from the health authorities. Pharmacy technicians have a
vocational qualification after education and practical
training and, as front shop staff in the pharmacy, can
provide all services, except independently dispensing
PD. For instance, they can ask customers about their use
of DS. However, they are trained to consult a pharmacist
whenever they feel unqualified to solve a problem.
In this study, the home care service is defined as a
public well-fare system available to all inhabitants in
need, and the backbone of the day-to-day care of
community-dwelling people in need of help with medi-
cation or ADL-support. When a person needs help with
his or her PD, an interdisciplinary collaboration between
the pharmacy/pharmacist, GP, and home care service is
needed. Pharmacy employees therefore have daily con-
tact with home care service employees and are well
acquainted with this service.
Study information and an electronic questionnaire
(Questback formula, Questback AS, Oslo, Norway) were
sent by e-mail to pharmacy employees. To increase the re-
sponse rate, we sent three reminder e-mails to all partici-
pants. Questback was set up such that respondents could
not submit more than one questionnaire. The pharmacy
managers informed their employees of the survey and
provided the e-mail addresses of all employees who met
the inclusion criteria (i.e., in which only employees with
customer contact were invited to participate). The number
of eligible employees reported by the managers was used
to calculate the response rate. Figure 1 provides an over-
view of the study population and the recruitment process.
Questionnaire
No validated questionnaire was available that covered
our research aspects. Therefore, we designed a question-
naire specifically for this study. As part of this process,
we evaluated previous studies and consulted relevant
multidisciplinary experts (see acknowledgements). We
conducted a feasibility study with fifteen pharmacists
and pharmacy technicians to investigate the relevance
and readability of the questions and to evaluate the
length of the questionnaire. The final version took
10–20 min to complete and covered 35 items, see
Additional file 1 for a translated verion of the ques-
tionaire. For the present study, we included a subset
of items grouped in the following five domains:
1. Study population (gender, education and years of
professional experience);
2. Attitudes toward DS (personal DS use, beliefs about
positive and negative effects of DS, recommending
DS to customers unprompted);
3. Attribution of responsibility for the safety of
persons with dementia using DS and suggestions
for safety improvement. The employees were asked
to rank the following options addressing the
question “Where should the responsibility for the
safe use of DS by persons with dementia be
placed?”: patients themselves, caregivers, GPs, home
care services, pharmacies, or DS retailers. DS
retailers could be employees in health food stores,
internet retailers, complementary and alternative
medicine therapists, or others. We also asked the
respondents to rank the following suggestions on
how to ensure correct and safe use of DS by
persons with dementia: information from health
authorities to the general population, changes in
laws and regulations concerning DS, increased
effort from GPs (ask all patients about use of DS
and check for adverse events and interactions),
increased effort from home care services (convey
information about the use of DS to GPs or
pharmacists), increased effort from pharmacies
(check for interactions between DS and PD for all
customers who buy DS, inform GPs when
interactions are identified), or DS delivery in
multidose drug-dispensing systems together with
PD. The multidose drug-dispensing system was not
explained further as pharmacy employees are
familiar with this system and its implications. The
multidose dispensing-system is similar to the
Automated Medication Dispensing Systems and is
commonly used for PD in Scandinavian countries
[25]. A computer-controlled robot system dispenses
each patient’s drugs into disposable bags. All drugs
intended for one dosing occasion are gathered in
one dose unit bag labeled with patient data, drug
contents, and the date and time for intake. To
deliver DS through the multidose drug-dispensing
system, the use of DS would be identified by the
health-care system, and both the GP and pharmacist
would be responsible for checking for interactions
and judgement on safety. It would also facilitate the
distribution and administration of DS, thereby
avoiding overdoses and other consequences of
user error.
The questions about attributed responsibilities and
suggestions for improvements of safety were ordinal. Re-
spondents were asked to rank the six categories, result-
ing in a ranking scale from 1 to 6. We merged priorities
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2–4 into a medium-level responsibility category, and pri-
orities 5–6 into a least-responsible category. We were
mainly interested in to whom the respondents assigned
the most responsibility or what they believed would be
the best intervention. For this reason we did not merge
priorities 1 and 2. We believe unclear lines of responsi-
bility is an obstacle to the safe care of persons with de-
mentia who use DS. Therefore, we wanted to determine
where pharmacy employees placed this responsibility
and, additionally, where they placed themselves. In
imminent studies that are already designed, we plan to
ask caregivers, GPs, and employees in home care service
about their opinion on this same matter.
4. Professional practice behaviors related to the sale of
DS (questions about DS, where to find independent
scientific information about DS, informing
customers about potential adverse events from DS,
asking about PD use when selling DS and vice
versa, checking for interactions between DS and PD
(including methods for checking), and willingness
to answer questions about DS not bought in the
pharmacy)
5. Professional experience with persons with
dementia in general and related to DS in
particular (education on counselling persons with
dementia, experience with persons with dementia
who are unable to understand important
pharmaceutical information, routines for handling
communication problems with customers with
dementia, experience with unsafe use of DS
among persons with dementia, and routines for
handling customers with dementia who use DS
unsafely).
Five of the questions in the subset used in this study
were open-ended questions (which DS products they
believe have positive effects against dementia, routines
for handling communication problems, routines for
handling unsafe DS use by customers with dementia, in
which context they have received education on counsel-
ling persons with dementia, and methods for checking
for interactions between DS and PD), two were ordinal
(attributed responsibility, suggestions for improvement
of safety), and the remainder were dichotomous or
multiple-choice questions. It was not possible to add
free text in the questionnaire except for the open-
ended questions.
Ethics
The Regional Committee for Medical and Health
Research Ethics presented no objections to the study
design (2014/1385). As no patients were included, the
project was defined as “quality assurance”. The survey
did not collect personally identifiable information and
therefore was not accountable to the Norwegian Data
Protection Agency. All participants were given written
information about the study and informed that
submitting the questionnaire was considered to be study
consent.
Statistics
We used IBM SPSS (Statistical Package for the Social
Sciences) version 23.0 (IBM Corp., Armonk, NY, US) for
the statistical analyses. Data are presented as absolute
and relative frequencies. We used Pearson’s chi-
square test or Fisher’s exact test for categorical data.
P values < 0.05 were considered statistically significant.
Results
Study population
One hundred and five persons, 11% men (n = 12) and
89% women (n = 93), answered the questionnaire, result-
ing in a response rate of 52%. Of these respondents, 54%
were pharmacists, and 46% were pharmacy techni-
cians, see Fig. 1. Four percent had 0–1 year (n = 4),
27% had 1–5 years (n = 28), 37% had 6–15 years (n = 39),
and 32% had more than 16 years (n = 34) of professional
experience.
Attitudes toward DS
In total, 37% of the respondents (n = 39) reported that
they currently used or had previously used some type of
DS. Nine percent (n = 9) believed that some DS might
have symptomatic or prophylactic effects against demen-
tia. The following DS were reported to be effective by
the 10 respondents who answered this open-ended ques-
tion (descending order of frequency): omega-3-fatty
acids, Ginkgo biloba, folic acid, vitamin E, vitamin B,
vitamin C, flavonoids, lecithin, cranberries, garlic and
ginger. Fifty-nine percent of the respondents (n = 62)
agreed that DS could have potentially harmful effects on
users’ health, and more pharmacists than pharmacy
technicians agreed with this statement (Table 1). There
were no other differences between the pharmacists and
pharmacy technicians in attitudes toward DS.
Pharmacy employees who used DS themselves more
often recommended DS to customers unprompted
(54% of users (n = 21) vs. 23% of nonusers (n = 15),
p = 0.002). Of the 35% (n = 37) who recommended DS
unprompted to customers, 73% (n = 27) did so be-
cause they believed that DS have documented benefi-
cial effects, and 49% (n = 18) because they believed
that DS could cure or give symptomatic relief.
Twenty-seven percent (n = 10) recommended DS be-
cause they felt the customers wanted to buy DS, 16%
(n = 6) due to the pharmacy’s upselling policy and 3%
(n = 1) because they believed that the products did no
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harm. Of the 63% (n = 66) who never recommended
DS unprompted, 62% (n = 41) reported insufficient
knowledge of DS, 62% (n = 41) feared interactions
with PD, 42% (n = 28) feared adverse events, and 20%
(n = 13) did not believe DS to have positive effects (it
was possible to choose more than one reason). Two
respondents did not answer the question about
whether they recommended DS.
Attributed responsibility
When asked to rank the six options, the majority of the
respondents stated that GPs should be responsible for en-
suring the safe use of DS by persons with dementia (Fig. 2).
They assigned themselves a medium level of responsibility,
followed by home care services and caregivers. Only 2%
(n = 2) indicated that pharmacies should bear the greatest
responsibility. Patients themselves and their caregivers
were considered to bear the least responsibility.
Sixty-two percent (n = 65) of the pharmacy employees
chose GPs, while 36% (n = 38) chose pharmacies when
answering the following question: “Do you think GPs or
pharmacies should be responsible for routinely checking
for interactions between DS and PD in persons with de-
mentia who use DS?” Two respondents did not answer
this question.
Most employees gave the highest priority to increased
effort from GPs when asked to rank several options ad-
dressing the question “Which option is best to ensure
the correct and safe use of DS by persons with demen-
tia?” (Fig. 3). Increased effort from home care services
and pharmacies were ranked approximately equally at
medium priority.
Table 1 Pharmacists’ and pharmacy technicians’ attitudes toward dietary supplements
Pharmacist Pharmacy technicians Total p-valuea
n = 57 n = 48 n = 105
n % n % n %
Personal use of DS (past or current)b 25 44 14 29 39 37 0.131
Believe DS have effects against dementiab, c 5 9 4 8 9 9 0.172
Agrees that DS can cause harm to healthb, c 44 77 18 38 62 59 < 0.001
Recommend DS to customers unpromptedd 21 37 16 33 37 35 0.369
DS Dietary supplements. Pharmacists include employees with a bachelor’s or master’s degree in pharmacy. Pharmacy technicians include employees with other
educational backgrounds, mainly pharmacy technicians (upper secondary school). aFisher’s exact test; bData are missing for one employee. cThe categories tested
were yes, no and do not know. dData are missing for two persons. Significant comparisons are printed in bold
Fig. 2 The employees’ ranking of responsibility for the safety of persons with dementia who use dietary supplements. The employees were given
six options addressing the question “Where should the responsibility for the safe use of DS by persons with dementia be placed?” Respondents
were asked to rank the six categories, resulting in a ranking scale from 1 to 6. We merged priorities 2–4 into a medium-level responsibility
category and priorities 5–6 into a least-responsible category. DS retailers could be employees in health food stores, internet merchandisers,
complementary and alternative medicine therapists, or others
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Professional practice behaviors
Questions about DS and the availability of independent
scientific information on DS
Most employees (96%, n = 101) had received questions
about DS from customers in the pharmacy, including
11% (n = 11) daily and 39% (n = 41) weekly. Two of the
respondents did not answer this question. There were
no differences between pharmacists and pharmacy
technicians. Eighty-one percent (n = 85) had been asked
to provide information about DS-products not sold in
their pharmacy. One respondents did not answer this
question. More pharmacists than pharmacy technicians
received questions about DS not sold in the pharmacy
(95% against 65%, p < 0.001). Twenty-seven percent
(n = 28) would answer the question about DS not sold
in the pharmacies. Eleven of the respondents did not
answer this question. More pharmacists than phar-
macy technicians provided information about DS not
sold in their pharmacy (χ 2 = 10.784 (2), p = 0.005)*.
Five percent of respondents reported access to inde-
pendent scientific information on all DS sold in their
pharmacy, 20% had information on most products,
and 30% had information on a few products. Forty-
two percent did not have such information available.
Three of the respondents did not answer this ques-
tion. There was no difference between pharmacists
and pharmacy technicians.
General safety procedures related to DS
Ninety percent of the pharmacy employees provided in-
formation on possible adverse events, including interac-
tions (48% confirmed that they informed customers
about potential adverse events, including interactions;
42% indicated that they did this sometimes). Addition-
ally, 82% checked for interactions at least sometimes,
while 16% did this as a routine (Table 2). More pharma-
cists than pharmacy technicians provided information
on possible adverse events and asked about the co-use
of DS and PD, but there was no difference in checking
for interactions. A minority of the respondents (14
pharmacy technicians and 25 pharmacists) answered the
question about which sources they used to check for in-
teractions. Among pharmacy technicians, five asked
pharmacists to perform the interaction analysis, five ana-
lyzed it themselves with the help of various Norwegian
databases, and four sometimes checked themselves and
sometimes asked a pharmacist to check. Most pharma-
cists used various internet sources, mainly webpages or-
ganized by official health authorities, e.g., relis.no (the
official web page of the Norwegian Pharmacovigilance
centers. These centers are run by Norwegian Health
Authorities. Relis.no answers questions about adverse
events and interactions from PD and DS). One pharma-
cists used only the product-dependent medication
information leaflet. We found no difference in safety
procedures depending on the employees’ attitudes
toward DS. Believing that DS have no negative effects
was not associated with less thorough safety routines,
specifically, performing interaction analyses (p = 0.328),
asking about the co-use of DS when dispensing PD
(p = 0.374), asking about the co-use of PD when selling
DS (χ2 = 3.86(6), p = 0.526)* and informing about ad-
verse events including interactions (p = 0.344). Statistics
were performed using Fisher’s exact test and chi square
Fig. 3 Pharmacy employees’ opinions on how to improve the safety of persons with dementia who use dietary supplements. DS, dietary
supplements. The employees were given six alternatives on how to ensure the correct and safe use of DS. Respondents were asked to rank the
six categories resulting in a ranking scale from 1 to 6. We merged priorities 2–4 into a medium-level priority category and priorities 5–6 into a
lowest-priority category
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test*. The same categories were tested as in Table 2
(that is, yes, no, and sometimes).
Professional experience with customers with dementia, both
in general and related to DS
Fifty-three percent (n = 56) had experienced customers
who were unable to understand important pharmaceut-
ical information because of cognitive problems; 26%
(n = 27) were uncertain, while 21% (n = 22) had never
been in this situation. More pharmacists than pharmacy
technicians had experienced this situation (χ 2 =
9.685(2), p = 0.008)*. The open-ended question about
routines for handling communication problems was
answered by 54 respondents, of which 31 reported that
their pharmacy lacked routines to handle this type of
communication problem. The respondents mentioned the
following three interventions (in decreasing frequency):
making contact with the caregiver/GP/home care service,
oral or written information given to the person with de-
mentia, and taking the initiative for the client/person with
dementia to have his or her medication dispensed by the
home care service in the multi-drug-dispensing system
(mentioned only by two respondents). Ten of the 31 re-
spondents who stated that their pharmacy lacked a rou-
tine, mentioned interventions that had taken place in their
pharmacy. Six percent of the employees had received edu-
cation on counselling persons with dementia. Three re-
spondents did not answer this question. When asked in
which context the respondents had received dementia
education, only six respondents who had received such
Table 2 Pharmacy employees’ professional practice behaviors related to dietary supplements
Pharmacists Pharmacy technicians Total p-value
n = 57 n = 48 n = 105
n % n % n %
Give information on adverse events and possible interactionsa, b 0.022
Yes 30 53 21 44 51 48
Sometimes 26 46 18 38 44 42
No 1 2 8 17 9 9
Ask customers about PD use when selling DSa, b 0.021
Always 15 26 11 23 26 25
Sometimesc 41 72 28 58 69 66
Depending on the customers’ health 9 16 0 0 9 9
Depending on the type of DS 32 56 28 58 60 57
Never 1 2 8 17 9 8
Ask customers about DS use when dispensing PDa, d 0.002
Always 0 0 2 4 2 2
Sometimes 32 56 12 25 44 42
Never 24 42 33 69 57 54
Routinely check for interactions between DS and PDe, f 0.409
Always 7 12 10 21 17 16
Sometimesf 40 70 28 58 68 65
In certain patients groups 12 21 3 6 15 14
For certain DS 34 60 18 38 52 50
For certain PD 16 28 17 35 33 31
Never 10 18 7 15 17 16
DS dietary supplements, PD prescription drugs
Pharmacists include employees with bachelor’s or master’s degree in pharmacy. Pharmacy technicians include employees with other educational backgrounds,
mainly pharmacy technicians (upper secondary school)
aStatistics are from Fisher’s exact test. The answers always, sometimes and never are included
bData for one employee are missing
cRespondents who confirmed that they asked customers about PD when selling DS depending on the customers’ health or depending on the type of DS were
merged into the category “Sometimes”
d Data for two employees are missing
e Data for three employees are missing
fStatistics are from the chi-square test
gIt was possible to give more than one answer to this question. Respondents who confirmed that they checked for interactions in one or more of the following
cases: certain patient groups, for certain DS or for certain PD, were merged into the category “Sometimes”
Significant comparisons are printed in bold
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education answered this question, two of whom had re-
ceived this training during nursing education and one dur-
ing five years of employment at a dementia department of
a nursing home. The rest stated that they received this
education during their professional education without fur-
ther specification.
Eight percent (n = 8) of the employees (seven pharma-
cists and one pharmacy technicians) had experienced per-
sons with dementia with unsafe use of DS. When asked
“How do you act professionally when you discover such a
problem”, only five respondents answered the question,
one contacted the caregivers, and the others tried to in-
form the persons with dementia more thoroughly about
the hazards and encouraged them to contact their GPs.
Statistics were performed using chi square test*.
Discussion
Interpretation of the results
This study revealed that the pharmacy employees had a
rather conservative attitude toward the use of DS. A
minority of the respondents (9%) believed DS to be ef-
fective against dementia; a majority (59%) agreed that
DS could cause harm. One-third of the respondents
(37%) were DS users themselves. We have not found
other studies addressing the question of the effectiveness
of DS against dementia, but the proportion of pharma-
cists who agree with the general statement that most
DS/herbs/natural products are clinically effective has
been found to vary from 19 to 48% [20, 26]. Our results
regarding perceived health risks are in line with those of
a systematic review reporting that 50% of pharmacists
believed DS to have potentially harmful effects [20].
Interestingly, even though some employees did not think
that DS could have negative effects, this attitude did not
seem to influence their counselling or safety procedures.
Previous studies have reported past or current DS use
by 53–66% of pharmacists [26–28]. In line with the
results of other studies, our results confirm that
personnel who use DS themselves more often recom-
mend DS to their customers [26, 27] possibly due to a
generally more positive attitude toward DS among self-
users [27]. Other studies have suggested that 40–91% of
pharmacists recommend DS to customers [20, 26, 27].
These studies do not specify whether the recommenda-
tions were unprompted or resulted from customers’
requests, except in one study where 38% of the pharma-
cists recommended DS unprompted [26], which is com-
parable to our findings (35%). The most common reason
for recommending DS among our respondents was an
assumed documented effect. The most common reasons
for not recommending were lack of knowledge of DS
and fear of interactions between DS and PD, in line with
the results of a previous qualitative study [29]. We find
it reassuring that upselling was an uncommon reason
for recommending DS.
Studies have identified potentially clinically relevant
interactions between DS and PD in persons with demen-
tia [6, 12]. Together with a lack of help with DS admin-
istration [12], these interactions indicates that at least
some persons with dementia might be exposed to health
risk (e.g., overdose and adverse effects) because of their
DS use. Previous studies have highlighted the need for
pharmacists to routinely document, monitor and inquire
about customers’ use of DS [20]. Our results showed
that pharmacy employees perceive themselves and home
care service employees as contributors to safeguarding
the use of DS by persons with dementia, but pharmacy
employees suggest that GPs should be the main respon-
sible care-taker in maintaining patient safety. Eight
percent had experienced unsafe use of DS among cus-
tomers with dementia. This finding might indicate that
unsafe use is an infrequent problem, or that pharmacy
employees do not possess the means necessary to identify
such problems. Necessary means would include know-
ledge of dementia and resources for proper counselling,
including routines for identifying problematic use.
First, pharmacy employees might have limited know-
ledge of dementia. Studies investigating general know-
ledge of dementia among pharmacists and final year
pharmacy students have indicated potential for improve-
ments in knowledge of risk factors, caregiving issues and
the pharmacological management of Alzheimer’s disease
[30]. We did not measure the level of knowledge of de-
mentia as such but did notice that the respondents
stated that they had not been educated on counselling
persons with dementia.
Second, our study suggests a lack of resources and
routines for counselling persons with dementia on their
use of DS. Norwegian pharmacies do not have access to
medical records, which limits the possibility of identify-
ing users’ dementia disease. Even if employees are aware
of customers’ cognitive problems, they are unlikely to
have knowledge on DS use and the conditions of such
use unless they specifically ask about it. As the majority
of persons with dementia buy their DS from health food
shops or on the internet [12], it is difficult to intercept
their DS use at the pharmacy. Additionally, as impaired
insight is a common feature of dementia, the persons
themselves might say the use is unproblematic when in
fact it is not. Not being fully informed about DS use
makes interaction analyses uncertain. Our results
suggest shortcomings in employees’ safety routines, as
only 2% routinely asked about the co-use of DS when
dispensing PD and only a minority would provide
information about DS bought outside the pharmacy.
Moreover, as shown by others, pharmacy employees lack
independent scientific information on most of the DS
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sold in their pharmacies [26], which may influence their
motivation to take on the responsibility [19]. Formulat-
ing legislation to clarify the legal and professional role of
pharmacists with respect to DS could make it easier to
take on the responsibility [31].
Our results suggest that pharmacy technicians have
less stringent procedures than pharmacists, as they
inquire about the co-use of DS and PD less often. They
also inform patients less often about side effects and
about DS-products not sold in the pharmacy. This fact
is important, as pharmacy technicians receive questions
about DS as often as pharmacists. Persons with demen-
tia and their caregivers are more likely to purchase DS
from a pharmacy technician than from a pharmacist
because there are as many pharmacy technicians as
pharmacists in Norwegian pharmacies, and pharmacy
technicians sell more over-the-counter products while
pharmacists work more with prescriptions. The differ-
ence in professional practice behaviors between pharma-
cists and pharmacy technicians demonstrated here and
in one other study [22] might be explained by higher
knowledge level regarding PD and DS among pharma-
cists due to different education levels. It could also
reflect a more strongly perceived professional responsi-
bility among pharmacists to give evidence-based advice
[32]. Only a minority of pharmacy technicians agreed
with the statement that DS can cause harm to health.
We have not, as mentioned earlier, shown any connec-
tion between this belief and the presence of less strict
safety routines.
Compared with increased effort from health personnel,
the remaining measures suggested to ensure safe use of
DS by persons with dementia were less popular. These
included changes in laws and regulations, information
from health authorities and dispensing DS in a multi-
dose drug-dispensing system (drug-dispensing system).
Few respondents were positive toward including DS in a
drug-dispensing system. One explanation could be that
the employees do not consider the reconciliation of DS
to be feasible, either due to a lack of studies testing DS
safety [33], lack of independent scientific information
[34], or other reasons. In addition, some products, such
as transparent tablets, large tablets, oral lyophilisates,
tablets with a short shelf-life and tablets that cannot be
stored at room temperature, are excluded from the
drug-dispensing system because of technical limitations
(Annette Vik Jøsendal, Apotek 1, personal communica-
tion). However, this is true for PD as well as DS.
As mentioned earlier, only a minority of pharmacy
employees considered actions outside the primary
health-care system to be important. Changes in laws and
regulations could enforce control over the content of DS
products and regulate both DS retailers’ and health-care
personnel’s professional conduct more thoroughly,
including the provision of clear lines of responsibility.
However, enforcement would also require increased re-
sources. Information campaigns from health authorities
might be less effective due to difficulties in reaching per-
sons with dementia.
Methodological considerations
We included pharmacy employees using minimal exclu-
sion criteria to maintain external validity. The response
rate was adequate compared with those in similar stud-
ies [20], but the limited number of respondents may
weaken the study power and generalizability. The study
population is representative of the Norwegian setting in
terms of the gender distribution [23]. However, em-
ployees with a pharmacy degree were overrepresented.
Our study population comprised 32% master’s degrees,
22% bachelor’s degrees, and 46% technicians (including
others), while the national distribution is (by Des 2017)
25% master’s degrees, 19% bachelor’s degrees, and 56%
pharmacy technicians (including others) [23]. Our
demographic findings are comparable to those of other
surveys among Norwegian pharmacy employees per-
formed in different geographical areas [35, 36]. Consid-
ering this potential limitation, the study findings may be
generalizable to pharmacy employees in other countries
with similar health-care systems, pharmacies and educa-
tion programs, particularly Swedish and Finnish pharma-
cies, which also employ bachelor pharmacists [37]. Few
studies have evaluated the use of DS by the Norwegian
general population, but available data indicate higher use
among Scandinavian women than in women from
southern Europe [38]. A report from the Norwegian
Food Authority found that 500 Norwegian respondents
use an average of 3.7 DS. As an average for the Nordic
countries, the respondents used 3.6 different products
[39]. We believe, however, that the question regarding
pharmacy employees’ professional conduct and responsi-
bility toward customers with dementia who buy DS is
relevant from a global perspective.
Even though we provided written information stating
how we defined DS of interest, we cannot determine if
the definition was clear to all employees. Similarly, we
do not know if all employees shared a common inter-
pretation of the word dementia, since we did not give a
specific definition.
Few respondents answered the question on how the
safety of persons with dementia who use DS could be
improved. The reason could be that they disagreed with
the need for improvement, and this answer should have
been included as a possible response. Another reason
could be that they found the ranking difficult. Further
specification of the options “Information from health
authorities to the general population”, and “Changes in
laws and regulations concerning DS” should also have
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been provided for clarity, such as “Information from
health authorities to the general population about DS”
and "Changes in laws and regulations concerning DS (in-
dicates increased control of the DS content, such as in-
creased testing for toxic effects, because DS currently
has less strict safety routines than PD). Further specifica-
tion might have increased the response rate to these
questions and increased the certainty of the respondents
about their answers. Regarding the option “increased ef-
fort from the home care service”, we could also have
been more specific. A suggested specification regarding
this question could have been, “If the home care service
discovers unsafe use of DS by persons with dementia,
they should convey this information to the GP or phar-
macy”. The question about work length, used to describe
the study-population, had wording that might have led
to uncertainty among respondents who had worked
exactly 16 years. The response rate to this question was
100%, so this uncertainty did not stop respondents from
answering. Twenty-nine percent of the pharmacy techni-
cians answered that they routinely informed patients/
customers about DS when dispensing PD. This question
should have been posed to pharmacists only, as both dis-
pensing PD and asking about co-use of other products
are the pharmacist’s duties after the technician has pre-
pared the prescription. Based on our experience from
pharmacy practice, we believe that communication
about co-use would have taken place in close cooper-
ation with a pharmacist. We also think the proportion
who answered yes was very high in both groups; two
technicians even said they always asked, which suggests
some level of “eager to please” bias. The question “Do
you supply information on adverse events from DS
including possible interactions?” was provided with the
options yes, no, and sometimes. A further specification
concerning when to answer yes or sometimes was not
provided, which could have led to inconsistent re-
sponses. However, when the option yes is provided as a
different response to sometimes, it implies a regular
intervention. The response rate was 99% to this ques-
tion, as one respondent did not answer. The main differ-
ence between pharmacists and pharmacy technicians
was that more pharmacy technicians answered no to this
question.
The study design made it necessary for the partici-
pants to answer electronically. This could have induced
some obstacles to participation; however, it was pos-
sible to answer by using the pharmacy’s computer, so it
was not necessary to possess a personal computer to
participate.
Implications and future research
Currently, there is a focus on dementia-friendly pharma-
cies and the special needs of persons with cognitive
problems [40]. We recommend clearly defined routines
to handle communication problems and to make exist-
ing routines known to all employees. The focus on safe
sale of DS in general should be improved. Frequent
assessments of potential interactions and routine inquir-
ies about DS, whether or not they are bought in the
pharmacy, are needed, as well as adequate independent
scientific information on all products sold in the phar-
macy. If pharmacies were to initiate actions to improve
these measures, a longitudinal study of the effect of such
an intervention would be recommended.
We believe that multidisciplinary collaboration among
pharmacists, GPs, home care service employees and
caregivers can ensure the safe use of DS by persons who
are incapable of handling the use themselves due to de-
mentia. First, the use needs to be identified. Second, it is
important to assess interactions between DS and PD and
potential adverse reactions. Third, the team needs to
consider the health benefits of using DS and recommend
use or discontinuation. If use is to be continued, it is
important to plan for safe administration, for instance
administration by the home care service. In all steps, the
involvement of the patients or caregivers is recommended.
Conclusion
The pharmacy employees showed a conservative attitude
toward DS in general and had limited experience with
problematic DS use among persons with dementia. They
did not rate themselves as primarily responsible for the
safety of persons with dementia who use DS. Contribut-
ing factors to this view may be the lack of independent
scientific information on DS product, limited informa-
tion on customers’ medical conditions and limited
knowledge on how to communicate with persons with
dementia. The roles and responsibilities concerning the
safety of persons with dementia using DS need to be
clearly defined. We suggest collaborations between the
pharmacy and the GP that preferably include home care
services and caregivers.
Additional file
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